1. Pepin M et al: Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 342(10):673-680, 2000
2. Plomp AS et al: Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. Am J Med Genet A 152A(4):1049-1058, 2010
3. Koulaouzidis A, Bhat S, Moschos J: Skin manifestations of liver diseases. Ann Hepatol 6(3):181-184, 2007
4. Murtagh FE et al: Symptoms in advanced renal disease: A cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J Palliat Med 10(6):1266-1276, 2007
5. Vahlquist A, Stenstrom E Torma H: Vitamin A and
beta-carotene concentrations at different depths of the epidermis: A preliminary study in the cow snout.
Ups J Med Sci 92(3):253-257, 1987
6. Murakami K et al: Serum levels of 5-s-cysteinyldopa are correlated with skin colors in hemodialysis patients but not in peritoneal dialysis patients. Blood Purif 28(3):209-215, 2009
7. Viraben R, Couret B, Gorguet B: Disseminated reticulate hypomelanosis developing during primary biliary cirrhosis. Dermatology 195(4):382-383, 1997
8. Smith KE, Fenske NA: Cutaneous manifestations of
alcohol abuse.
J Am Acad Dermatol 43(1 Pt 1):1-16; quiz 16-18, 2000
9. Jones EA, Bergasa NV: Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 14(1):33-40, 2000
10. Jones EA, Neuberger J, Bergasa NV: Opiate antagonist therapy for the pruritus of cholestasis: The avoidance of opioid withdrawal-like reactions. Q J Med 95(8):547-552, 2002
11. Bergasa NV et al: Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. J Am Acad Dermatol 41(3 Pt 1):431-434, 1999
12. Bergasa NV et al: Effects of
naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.
Ann Intern Med 123(3):161-167, 1995
13. Wolfhagen FH et al: Oral
naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.
Gastroenterology 113(4):1264-1269, 1997
14. Zein CO, Lindor KD: Latest and emerging therapies for primary biliary cirrhosis and sclerosing cholangitis. Curr Gastroenterol Rep 12(1):13-22, 2010
15. Szepietowski JC, Schwartz RA: Uremic pruritus. Int J Dermatol 37(4):247-253, 1998
16. Stahle-Backdahl M: Uremic pruritus. Semin Dermatol 14(4):297-301, 1995
17. Gilchrest BA et al: Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol 118(3):154-156, 1982
18. Szepietowski JC, Salomon J: Uremic pruritus: Still an important clinical problem. J Am Acad Dermatol 51(5):842-843, 2004
19. Mettang M, Weisshaar E: Pruritus: Control of itch in patients undergoing dialysis. Skin Therapy Lett 15(2):1-5 2010
20. Gilchrest BA, Rowe JW, Mihm MC Jr: Clinical and histological skin changes in chronic renal failure: Evidence for a dialysis-resistant, transplant-responsive microangiopathy. Lancet 2(8207):1271-1275, 1980
21. Gilchrest BA et al: Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 297(3):136-138, 1977
22. Gilchrest BA et al: Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 91(1):17-21, 1979.
23. Schwartz I, FIaina A: Management of uremic pruritus. Semin Dial 13(3):177-180, 2000
24. Kyriazis J, Glotsos J: Dialysate calcium concentration of ≤ =1.25 mmol/l: Is it effective in suppressing uremic pruritus? Nephron 84(1):85-86, 2000
25. De Marchi S et al: Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 326(15):969-974, 1992
26. Yoshimoto-Furuie K et al: Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron 81(2):151-159, 1999
27. Szepietowski JC, Reich A, Szepietowski T:
Emollients with endocannabinoids in the treatment of uremic pruritus: Discussion of the therapeutic options.
Ther Apher Dial 9(3):277-279, 2005
28. Pauli-Magnus C et al: Short-term efficacy of
tacrolimus ointment in severe uremic pruritus.
Perit Dial Int 20(6):802-803, 2000
29. Johns MK: Skin wrinkling in cystic fibrosis. Med Biol Illus 25(4):205-210, 1975
30. Hill CL et al: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96-100, 2001
31. Sparsa A et al: Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 138(7):885-890, 2002
32. Spiera R, Kagen L: Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 10(6):556-561, 1998
33. Kurzrock R, Cohen PR: Cutaneous paraneoplastic syndromes in solid tumors. Am J Med 99(6):662-671, 1995
34. Rothe MJ, Bialy TL, Grant-Kels JM: Erythroderma. Dermatol Clin 18(3):405-415, 2000
35. Ryan AS, Goldsmith LA: Nutrition and the skin. Clin Dermatol 14(4):389-406, 1996
36. Tosti A. The nail in systemic disease. In: Diseases of the Nails and Their Management, edited by R Baran, Dawber R. Oxford, Blackwell Scientific Publications, 1994
37. Terry R: White nails in hepatic cirrhosis. Lancet 266(6815):757-759, 1954
38. Bull RH, Fenton DA, Mortimer PS: Lymphatic function in the yellow nail syndrome. Br J Dermatol 134(2):307-312, 1996
39. Davis MD et al: Natural history of erythromelalgia: Presentation and outcome in 168 patients. Arch Dermatol 136(3):330-336, 2000
40. Cohen JS: Erythromelalgia: New theories and new therapies. J Am Acad Dermatol 43(5 Pt 1):841-847, 2000
41. Davis MD, Rooke T: Erythromelalgia. Curr Treat Options Cardiovasc Med 8(2):153-165, 2006
42. Cohen JS: High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Ann Pharmacother 36(2):255-260, 2002
43. Sandroni P, Davis MD: Combination gel of 1%
amitriptyline and 0.5%
ketamine to treat refractory erythromelalgia pain: a new treatment option?
Arch Dermatol 142(3):283-286, 2006
44. Zyluk A: Scoring system in the assessment of the clinical severity of reflex sympathetic dystrophy of the hand. Hand Clin 19(3):517-521, xi, 2003
45. Zyluk A: The sequelae of reflex sympathetic dystrophy. J Hand Surg [Br] 26(2):151-154, 2001
46. Zyluk A: Complex regional pain syndrome type I. Risk factors, prevention and risk of recurrence. J Hand Surg [Br] 29(4):334-337, 2004
47. Nambu M, Kaneko KIijima T: Biochemical and clinical study of muscle atrophy at thenar and hypothenar eminences in patients with cirrhosis. Liver 16(1):19-22, 1996
48. Foutch PG et al: Cutaneous vascular spiders in cirrhotic patients: Correlation with hemorrhage from esophageal varices. Am J Gastroenterol 83(7):723-726, 1988
49. Li CP et al: Role of substance P in the pathogenesis of spider angiomas in patients with nonalcoholic liver cirrhosis. Am J Gastroenterol 94(2):502-507, 1999
50. Li CP et al: Spider angiomas in patients with liver cirrhosis: Role of vascular endothelial growth factor and basic fibroblast growth factor. World J Gastroenterol 9(12):2832-2835, 2003
51. Li CP et al: Spider angiomas in patients with liver cirrhosis: Role of alcoholism and impaired liver function. Scand J Gastroenterol 34(5):520-523, 1999
52. Marinkovich MP: Update on inherited bullous dermatoses. Dermatol Clin 17(3):473-485, vii, 1999
53. Lekas MD, Thayer WR Jr: Dysphagia from benign mucocutaneous pemphigoid. Ear Nose Throat J 67(2):113-116, 1988
54. Abraham SC et al: Esophageal lichen planus: case report and review of the literature. Am J Surg Pathol 24(12):1678-1682, 2000
55. Shimizu H, Tan Kinoshita MT, Suzuki H: Darier's disease with esophageal carcinoma. Eur J Dermatol 10(6):470-472, 2000
56. Pickering MC, Haskard DO: Behcet's syndrome. J R Coll Physicians Lond 34(2):169-177, 2000
57. Howel-Evans W, Clarke CA, Sheppard PM: Carcinoma of the oesophagus with keratosis palmaris et plantaris (tylosis): A study of two families. Q J Med 27(107):413-429, 1958
58. Sjogren RW: Gastrointestinal features of scleroderma. Curr Opin Rheumatol 8(6):569-575, 1996
59. Miric D et al: Dermatological indicators of coronary risk: A case-control study. Int J Cardiol 67(3):251-255, 1998
60. Lotufo PA et al: Male pattern baldness and coronary heart disease: The Physicians' Health Study. Arch Intern Med 160(2):165-171, 2000
61. Norgett EE et al: Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 9(18):2761-2766, 2000
62. Rhodes AR et al: Mucocutaneous lentigines, cardiomucocutaneous myxomas, and multiple blue nevi: The “LAMB” syndrome. J Am Acad Dermatol 10(1):72-82, 1984
63. Moder KG, Miller TD, Tazelaar HD: Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74(3):275-284, 1999
64. Marie I et al: Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45(4):346-354, 2001
65. Krafchik BR: Neonatal lupus erythematosus. Adv Exp Med Biol 455:23-26, 1999
66. Steen VD, Medsger TA Jr: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11):2437-2444, 2000
67. Haitjema T et al: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): New insights in pathogenesis, complications, and treatment. Arch Intern Med 156(7):714-719, 1996
68. Fried M, Mana F, Urbain D: Cyanosis and cirrhosis of liver: Hepatopulmonary syndrome. Ned Tijdschr Geneeskd 144(37):1790-1793, 2000
69. Alcolado R et al: Systemic arteriovenous malformations: A feature of advanced liver disease. Gut 35(8):1145-1147, 1994
70. Mellor A, Soni N: Fat embolism. Anaesthesia 56(2):145-154, 2001
71. Valencia IC, Colsky A, Berman B: Multicentric reticulohistiocytosis associated with recurrent breast carcinoma. J Am Acad Dermatol 39(5 Pt 2):864-866, 1998
72. Baydur A et al: Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 120(1):102-108, 2001
73. Baydur A et al: Microscopic pulmonary embolisation of an indwelling central venous catheter with granulomatous inflammatory response. Eur Respir J 26(2):351-353, 2005
74. McCarthy RE III, Kasper EK: A review of the amyloidoses that infiltrate the heart. Clin Cardiol 21(8):547-552, 1998
75. Makol A et al: Lymphomatoid granulomatosis masquerading as interstitial pneumonia in a 66-year-old man: A case report and review of literature. J Hematol Oncol 2:39, 2009
76. Keane MP, Lynch JP III. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 55(2):159-166, 2000
77. Veeraraghavan S, Sharma OP: Progressive systemic sclerosis and the lung. Curr Opin Pulm Med 4(5):305-309, 1998
78. Oksuzoglu BC et al: Blue rubber bleb nevus syndrome. Am J Gastroenterol 91(4):780-782, 1996
79. Dinkel HP, Maroske J, Schrod L: Sonographic appearances of the abdominal manifestations of hereditary angioedema. Pediatr Radiol 31(4):296-298, 2001
80. Bork K, Barnstedt SE: Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 161(5):714-718, 2001
81. von und zu Fraunberg M, Kauppinen R: Diagnosis of variegate porphyria–hard to get? Scand J Clin Lab Invest 60(7):605-610, 2000
82. Hartmann K, Henz BM: Mastocytosis: Recent advances in defining the disease. Br J Dermatol 144(4):682-695, 2001
83. Hartmann K, Bruns SB, Henz BM: Mastocytosis: Review of clinical and experimental aspects. J Investig Dermatol Symp Proc 6(2):143-147, 2001
84. Hartmann K, Henz BM: Classification of cutaneous mastocytosis: A modified consensus proposal. Leuk Res 26(5):483-484; author reply 485-486, 2002
85. Hartmann K, Henz BM: Cutaneous mastocytosis – clinical heterogeneity. Int Arch Allergy Immunol 127(2):143-146, 2002
86. Brady RO, Schiffmann R: Clinical features of and recent advances in therapy for Fabry disease. JAMA 284(21):2771-2775, 2000
87. Tizard EJ: Henoch-Schonlein purpura. Arch Dis Child 80(4):380-383, 1999
88. Gunasekaran TS: Henoch-Schonlein purpura: what does the “rash” look like in the gastrointestinal mucosa? Pediatr Dermatol 14(6):437-440, 1997
89. Lankisch MR et al: Acute abdominal pain as a leading symptom for Degos' disease (malignant atrophic papulosis). Am J Gastroenterol 94(4):1098-1099, 1999
90. Harned RK, Buck JL, Sobin LH: The hamartomatous polyposis syndromes: Clinical and radiologic features. AJR Am J Roentgenol 164(3):565-571, 1995
91. Tsao H: Update on familial cancer syndromes and the skin. J Am Acad Dermatol 42(6):939-969; quiz 970-972, 2000
92. Doxey BW, Kuwada SK, Burt RW: Inherited polyposis syndromes: Molecular mechanisms, clinicopathology, and genetic testing. Clin Gastroenterol Hepatol 3(7):633-641, 2005
93. Friedman S et al: Intravenous
cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease.
Inflamm Bowel Dis 7(1):1-7, 2001
94. Miller AM et al: Rapid response of severe refractory metastatic Crohn's disease to
infliximab.
J Gastroenterol Hepatol 16(8):940-942, 2001
95. Bem J, Bradley EL III: Subcutaneous manifestations of severe acute pancreatitis. Pancreas 16(4):551-555, 1998
96. Geary RJ, Long LL, Mutasim DF: Bowel bypass syndrome without bowel bypass. Cutis 63(1):17-20, 1999
97. Steen V: Targeted therapy for systemic sclerosis. Autoimmun Rev 5(2):122-124, 2006
98. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 340(11):858-868, 1999
99. Kulke M: Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol 6(5):397-3409, 2005
100. Usman A et al: Lichenoid eruption following hepatitis B vaccination: First North American case report. Pediatr Dermatol 18(2):123-126, 2001
101. Criado PR et al: Two case reports of cutaneous adverse reactions following hepatitis B vaccine: Lichen planus and granuloma annulare. J Eur Acad Dermatol Venereol 18(5):603-606, 2004
102. Wolf F et al: Generalized granuloma annulare and hepatitis B vaccination. Eur J Dermatol 8(6):435-436, 1998
103. Breitschwerdt B et al: Hepatitis virus-related and ethanol-induced chronic liver disease with or without cryoglobulins–is there a difference concerning clinical or laboratory manifestation? Infection 27(4-5):248-251, 1999
104. Nan DN et al: Atypical skin lesions associated with mixed cryoglobulinaemia and hepatitis C virus infection in a cocaine-consuming patient. Br J Dermatol 143(6):1330-1331, 2000
105. Baleviciene G, Maciuleviciene R, Schwartz RA: Papular acrodermatitis of childhood: the Gianotti-Crosti syndrome. Cutis 67(4):291-294, 2001
106. Tay YK: Gianotti-Crosti syndrome following immunization. Pediatr Dermatol 18(3):262, 2001
107. Tan E et al: Bullous Sweet's syndrome associated with acute hepatitis B infection: a new association. Br J Dermatol 143(4):914-916, 2000
108. Chia SC et al: Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 43(10):2177-2183, 1998
109. Farkas H et al: Acquired angioedema associated with chronic hepatitis C. J Allergy Clin Immunol 103(4):711-712, 1999
110. Hadziyannis SJ: Skin diseases associated with hepatitis C virus infection. J Eur Acad Dermatol Venereol 10(1):12-21, 1998
111. Carrozzo M, Gandolfo S: Oral diseases possibly associated with hepatitis C virus. Crit Rev Oral Biol Med 14(2):115-127, 2003
112. Beaird LM et al: Incidence of hepatitis C in lichen planus. J Am Acad Dermatol 44(2):311-312, 2001
113. Carrozzo M et al: Increased frequency of HLA-DR6 allele in Italian patients with hepatitis C virus-associated oral lichen planus. Br J Dermatol 144(4):803-808, 2001
114. Carrozzo M et al: Hepatitis C virus-associated oral lichen planus: is the geographical heterogeneity related to HLA-DR6? J Oral Pathol Med 34(4):204-208, 2005
115. Frankel AJ et al: Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 61:1044-1055, 2009
116. Inuzuka M et al: Acquired ichthyosis associated with dermatomyositis in a patient with hepatocellular carcinoma. Br J Dermatol 144(2):416-417, 2001
117. Nasr I et al: Kawasaki disease: an update. Clin Exp Dermatol 26(1):6-12, 2001
118. van Hoek B: The spectrum of liver disease in systemic lupus erythematosus. Neth J Med 48(6):244-253, 1996
119. Islam S, Riordan JW, McDonald JA: Case report: A rare association of primary biliary cirrhosis and systemic lupus erythematosus and review of the literature. J Gastroenterol Hepatol 14(5):431-435, 1999
120. Inagaki H et al: Idiopathic portal hypertension associated with systemic lupus erythematosus. J Gastroenterol 35(3):235-239, 2000
121. Morelli MS, O'Brien FX: Stevens-Johnson Syndrome and cholestatic hepatitis. Dig Dis Sci 46(11):2385-2388, 2001
122. Akimoto S et al: Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliary cirrhosis: A comparison with patients with systemic sclerosis alone. J Dermatol 26(1):18-22, 1999
123. Graham-Brown RA, Sarkany I, Sherlock S: Lichen planus and primary biliary cirrhosis. Br J Dermatol 106(6):699-703, 1982
124. Sowden JM et al: Isolated lichen planus of the nails associated with primary biliary cirrhosis. Br J Dermatol 121(5):659-662, 1989
125. Oleaga JM et al: Generalized lichen planus associated with primary biliar cirrhosis which resolved after liver transplantation. Acta Derm Venereol 75(1):87, 1995
126. Chu CY et al: Lichen planus with xanthomatous change in a patient with primary biliary cirrhosis. Br J Dermatol 142(2):377-378, 2000
127. Tadros T, Traber DL, Herndon DN: Hepatic blood flow and
oxygen consumption after burn and sepsis.
J Trauma 49(1):101-108, 2000
128. Tadros T, Traber DL, Herndon DN: Opposite effects of prostacyclin on hepatic blood flow and
oxygen consumption after burn and sepsis.
Ann Surg 239(1):67-74, 2004
129. Higgins E:
Alcohol, smoking and psoriasis.
Clin Exp Dermatol 25(2):107-110, 2000
130. Bode S, Gudmand-Hoyer E: Symptoms and haematologic features in consecutive adult coeliac patients. Scand J Gastroenterol 31(1):54-60, 1996
131. Kirby B et al: Abnormal liver function tests induced by
dapsone in a patient with dermatitis herpetiformis and primary sclerosing cholangitis.
Br J Dermatol 141(1):172-173, 1999
132. Kolbe RE et al:
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.
J Am Acad Dermatol 60(5):824-837 2009
133. Zachariae H: Liver biopsies and
methotrexate: A time for reconsideration?
J Am Acad Dermatol 42(3):531-554, 2000
134. Zachariae H, Sogaard H, Heickendorff L: Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm Venereol 69(3):241-244, 1989
135. Zachariae H et al: Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: Relation to liver fibrosis and arthritis. J Am Acad Dermatol 25(1 Pt 1):50-53, 1991
136. Zachariae H, Heickendorff L, Sogaard H: The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: A 10-year follow-up. Br J Dermatol 144(1):100-103, 2001
137. Zachariae H: Have methotrexate-induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies. Dermatology 211(4):307-308, 2005
138. Laharie D et al: Performance of transient elastography for the staging of liver fibrosis: A meta-analysis. Aliment Pharmacol Ther 23(11):1621-1628, 2006
139. Vyas R et al: Use of transient elastography for non-invasive monitoring of
methotrexate induced liver fibrosis. Oral Presentation to New Zealand Dermatological Society/Dowling Club, Christchurch, May 2010
140. Friedrich-Rust M et al: Performance of transient elastography for the staging of liver fibrosis: A meta-analysis. Gastroenterology 134(4):960-974, 2008
141. Worth RL: Calciphylaxis: Pathogenesis and therapy. J Cutan Med Surg 2(4):245-248, 1998
142. Hafner J et al: Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): A complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 33(6):954-962, 1995
143. Poh-Fitzpatrick MB, Masullo AS, Grossman ME: Porphyria cutanea tarda associated with chronic renal disease and hemodialysis. Arch Dermatol 116(2):191-195, 1980
144. Poh-Fitzpatrick MB, Sosin AE, Bemis J: Porphyrin levels in plasma and erythrocytes of chronic hemodialysis patients. J Am Acad Dermatol 7(1):100-104, 1982
145. Kelly MA, O'Rourke KD: Treatment of porphyria cutanea tarda with phlebotomy in a patient on peritoneal dialysis. J Am Acad Dermatol 44(2 Suppl):336-338, 2001
146. Stevens BR et al: Porphyria cutanea tarda in the setting of renal failure. Response to renal transplantation. Arch Dermatol 129(3):337-339, 1993
147. Sarkell B, Patterson JW: Treatment of porphyria cutanea tarda of end-stage renal disease with erythropoietin. J Am Acad Dermatol 29(3):499-500, 1993
148. Anderson KE et al: Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 322(5):315-317, 1990
149. Rapini RP, Herbert AA, Drucker CR: Acquired perforating dermatosis. Evidence for combined transepidermal elimination of both
collagen and elastic fibers.
Arch Dermatol 125(8):1074-1078, 1989
150. Farrell AM: Acquired perforating dermatosis in renal and diabetic patients. Lancet 349(9056):895-866, 1997
151. Morton CA et al: Acquired perforating dermatosis in a British dialysis population. Br J Dermatol 135(5):671-677, 1996
152. Patterson JW: Progress in the perforating dermatoses. Arch Dermatol 125(8):1121-1123, 1989
153. Haftek M et al: Acquired perforating dermatosis of diabetes mellitus and renal failure: further ultrastructural clues to its pathogenesis. J Cutan Pathol 20(4):350-355, 1993
154. Cowper SE et al: Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23(5):383-393, 2001
155. Cowper SE, Bucala R, LeBoit PE: Case 35-2004: Nephrogenic fibrosing dermopathy. N Engl J Med, 352(16):1723-1724; author reply 1723-1724, 2005
156. Cowper SE et al: Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356(9234):1000-1001, 2000
157. Weinreb JC, Abu-Alfa AK: Gadolinium-based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? Gadolinium-based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? J Magn Reson Imaging 30(6):1236-1239, 2009
158. Chaudhary K, Wall BM, Rasberry RD: Livedo reticularis: An underutilized diagnostic clue in cholesterol embolization syndrome. Am J Med Sci 321(5):348-351, 2001